Elevated DHEA in Postmenopausal Women
In a postmenopausal woman with elevated DHEA, immediately measure early morning total testosterone and DHEAS to exclude an androgen-secreting adrenal or ovarian tumor, which represents the most critical life-threatening diagnosis that must not be missed.
Initial Evaluation Algorithm
The evaluation must systematically exclude serious pathology before considering benign causes:
Step 1: Measure Critical Androgens
- Early morning total testosterone (8 AM, fasting)
- DHEAS level (not just DHEA)
- Perform these tests simultaneously to assess the full androgen profile 1
Step 2: Risk-Stratify Based on Results
High-Risk Features Requiring Urgent Imaging:
- DHEAS >600 µg/dL (16,000 nmol/L) → Strongly suggests adrenal tumor; obtain abdominal CT immediately 2
- Testosterone >2x upper limit of normal → Suggests ovarian or adrenal neoplasm 1
- Rapid onset of virilization (deepening voice, clitoromegaly, male-pattern baldness)
- DHEA levels markedly exceeding DHEAS → May indicate poorly differentiated adrenal tumor 3
If high-risk features present:
- Obtain pelvic ultrasound to evaluate for ovarian neoplasm or hyperthecosis 1
- Obtain abdominal CT if DHEAS markedly elevated to assess for adrenal mass 1, 2
Step 3: Exclude Other Endocrinopathies
Even with moderately elevated DHEA, assess for:
- 17-hydroxyprogesterone (early morning) to screen for nonclassic congenital adrenal hyperplasia, particularly in high-risk ethnic groups (Ashkenazi Jews, Hispanics, Slavics) 1
- Cushing's syndrome screening if clinical features present (central obesity, striae, proximal weakness): 24-hour urinary free cortisol, late-night salivary cortisol, or 1-mg overnight dexamethasone suppression test 3
- Thyroid function if other features suggest thyroid dysfunction 1
Understanding DHEA Physiology in Postmenopausal Women
Critical Context: DHEA and DHEAS are prohormones, not active androgens—they require peripheral conversion to testosterone and estradiol 4. In postmenopausal women, DHEA serves as the exclusive source of all sex steroids, as the ovary contributes approximately 20% to the DHEA pool but secretes no active estrogens or androgens directly 5.
Normal Variability: Serum DHEA in postmenopausal women shows remarkable interindividual variability with a 7.9-fold difference between 5th and 95th percentiles (0.55 to 4.34 ng/mL) 5. This wide distribution explains why some women remain asymptomatic while others experience significant symptoms despite similar menopausal status.
Age-Related Decline: DHEAS decreases approximately 1.5-2.8% per year with age, independent of menopause 4. However, a transient late perimenopausal rise in DHEAS of approximately 4% has been observed 4, which may explain some cases of mildly elevated levels.
When Elevation is Likely Benign
If tumor and endocrinopathy workup is negative, consider:
Physiologic Variations:
- Normal high-end of the wide physiologic range for postmenopausal women 5
- Transient perimenopausal elevation (if recently menopausal) 4
- Ovarian contribution (approximately 20% of total DHEA pool) 5
Medications/Conditions Affecting Measurement:
- Medications increasing SHBG (estrogens, tamoxifen, raloxifene) can alter interpretation 2
- Obesity and metabolic syndrome typically lower SHBG, increasing free androgen levels 1, 2
Management After Excluding Serious Pathology
If no tumor or endocrinopathy identified:
- No treatment required for asymptomatic elevation within the wide normal range
- Monitor clinically for development of virilization symptoms
- Repeat androgens in 3-6 months if borderline elevated or clinical concern persists
If symptomatic hyperandrogenism present (hirsutism, acne):
- Consider pharmacologic antiandrogen therapy (spironolactone, oral contraceptives if appropriate) or direct hair removal methods based on patient preference 1
- Note: Treatment decisions should be based on testosterone levels and clinical symptoms, not DHEA alone
Critical Pitfalls to Avoid
Failing to measure DHEAS alongside DHEA: DHEAS is more stable and better reflects adrenal androgen production 1
Missing adrenal tumors: Any DHEAS >600 µg/dL mandates imaging—these tumors can be malignant and life-threatening 3, 2
Relying on unreliable assays: Direct immunoassays for free testosterone are seriously flawed; use calculated free testosterone or equilibrium dialysis/ultrafiltration methods 4
Overlooking nonclassic CAH: Screen with 17-hydroxyprogesterone in appropriate ethnic groups or if family history present 1
Assuming DHEA supplementation is the cause: While DHEA supplementation increases testosterone and estradiol levels in postmenopausal women (particularly at doses ≥50 mg/day) 6, 7, verify whether the patient is actually taking supplements before attributing elevation to exogenous sources
The overriding principle: Elevated DHEA in a postmenopausal woman requires systematic exclusion of androgen-secreting tumors and endocrinopathies before reassurance, as these represent preventable causes of morbidity and mortality.